Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Gene-editing programmes have been slowly trickling into the clinic since 2005. But the pace is picking up. In the past year and a half alone, at least 11 such programmes entered the clinic in the US or EU. And 6 of these rely on CRISPR–Cas-based editors. With the clinical-stage pipeline now spanning ex vivo, immuno-oncology and in vivo applications, the genome-editing pipeline is taking form.